The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes after high-dose radiation in management of neuroendocrine neoplasms.
 
Katherine Chen
No Relationships to Disclose
 
Julia Whitman
No Relationships to Disclose
 
Alan Paciorek
No Relationships to Disclose
 
Eric K. Nakakura
Employment - Bayer (I); Bayer (I); Bayer (I); Bayer (I)
Stock and Other Ownership Interests - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics
Research Funding - Lexicon; Lexicon; Lexicon; Lexicon
 
Nicholas Fidelman
No Relationships to Disclose
 
Mary Uan-Sian Feng
Honoraria - Medivation/Astellas (I); Medivation/Astellas (I); Medivation/Astellas (I); Medivation/Astellas (I); Myriad Pharmaceuticals (I); Myriad Pharmaceuticals (I); Myriad Pharmaceuticals (I); Myriad Pharmaceuticals (I); Reflexion Medical; Reflexion Medical; Reflexion Medical; Reflexion Medical
Consulting or Advisory Role - GenomeDx (I); GenomeDx (I); GenomeDx (I); GenomeDx (I); Myriad Pharmaceuticals (I); Myriad Pharmaceuticals (I); Myriad Pharmaceuticals (I); Myriad Pharmaceuticals (I); NanoString Technologies (I); NanoString Technologies (I); NanoString Technologies (I); NanoString Technologies (I); Varian Medical Systems; Varian Medical Systems; Varian Medical Systems; Varian Medical Systems
Speakers' Bureau - Medivation/Astellas (I); Medivation/Astellas (I); Medivation/Astellas (I); Medivation/Astellas (I)
Research Funding - Celgene (I); Celgene (I); Celgene (I); Celgene (I); Varian Medical Systems (Inst); Varian Medical Systems (Inst); Varian Medical Systems (Inst); Varian Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for RadioType Dx, a biomarker test (I); Patent pending for RadioType Dx, a biomarker test (I); Patent pending for RadioType Dx, a biomarker test (I); Patent pending for RadioType Dx, a biomarker test (I)
Travel, Accommodations, Expenses - GenomeDx (I); GenomeDx (I); GenomeDx (I); GenomeDx (I)
 
Emily K. Bergsland
Leadership - More Health (I); More Health (I); More Health (I); More Health (I)
Stock and Other Ownership Interests - More Health (I); More Health (I); More Health (I); More Health (I)
Honoraria - UpToDate; UpToDate; UpToDate; UpToDate
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Crinetics Pharmaceuticals; Crinetics Pharmaceuticals; Crinetics Pharmaceuticals; Crinetics Pharmaceuticals; more health (I); more health (I); more health (I); more health (I)
Research Funding - Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Advanced Accelerator Applications (Inst); Merck; Merck; Merck; Merck; Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate; UpToDate; UpToDate; UpToDate
Travel, Accommodations, Expenses - Crinetics Pharmaceuticals; Crinetics Pharmaceuticals; Crinetics Pharmaceuticals; Crinetics Pharmaceuticals
 
Mekhail Anwar
No Relationships to Disclose